Consistent clinical cure rates against relevant pathogens, including S. pneumoniae and MSSA1-3
FOCUS 1 and FOCUS 2 Integrated Analysis1
Adapted from File T, et al. 2010.
FOCUS, ceFtarOline Community-acquired pneUmonia trial versuS ceftriaxone in hospitalised patients; MSSA, methicillin-susceptible Staphylococcus aureus; TOC, test of cure.
Safety profile consistent with other cephalosporins
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.